Announcement on Change of ""Drug Manufacturing License"
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
Hunan Fangsheng Pharmaceutical Co., Ltd. has announced a change to its Drug Manufacturing License. The license's validity has been extended and production details have been updated, including new production lines and products. The company assures that these changes will not impact its current production capacity or financial performance significantly. Investors are advised to remain cautious due to the inherent risks associated with pharmaceutical product development.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Fangsheng Pharmaceutical
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary
- Announcement on Drug Marketing Authorization Transfer
- Announcement on Obtaining Summary Report of Phase II Clinical Trial for Zhilong Tongluo Tablets
- Announcement on Implementation of Semi-annual Dividend Distribution for 2025
Later from Hunan Fangsheng Pharmaceutical
- Report for Q3 2025
- Announcement on Outline of the Q3 2025 Performance Briefing
- Announcement on Obtainment of the "Drug Registration Certificate" for Indobufen Tablets
- Announcement on Inclusion of Innovative Traditional Chinese Medicine Yangxue Qufeng Zhitong Granules in the National Medical Insurance Catalog (2025)
- Announcement on Holding Investor Reception Day
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical